Bowel Cancer Combo Fails to Improve Survival (CME/CE)

(MedPage Today) — Adding the targeted therapy cetuximab (Erbitux) to a standard chemotherapy regimen in advanced colorectal cancer did not extend life, researchers reported.

Post a Comment

Comments are closed.